| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aprea Therapeutics, Inc. | SVP, Chief Scientific Officer | Common Stock | 43,700 | $160,855 | $3.68 | 10 Mar 2022 | Direct |
| Aprea Therapeutics, Inc. | SVP, Chief Scientific Officer | Stock Option (right to Buy) | 100,000 | 10 Mar 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| APRE | Aprea Therapeutics, Inc. | 10 Mar 2022 | 2 | $0 | 4 | SVP, Chief Scientific Officer | 14 Mar 2022, 17:01 |
| APRE | Aprea Therapeutics, Inc. | 01 Oct 2021 | 3 | -$198,500 | 4 | SVP, Chief Scientific Officer | 05 Oct 2021, 17:01 |
| APRE | Aprea Therapeutics, Inc. | 20 Sep 2021 | 3 | -$101,250 | 4 | SVP, Chief Scientific Officer | 22 Sep 2021, 17:00 |